Norelgestromin And Ethinyl Estradiol
Generic Name: norelgestromin and ethinyl estradiol
Brand Names:
Zafemy
Norelgestromin and ethinyl estradiol is a transdermal contraceptive patch delivering approximately 150 mcg/day of norelgestromin and 35 mcg/day of ethinyl estradiol, indicated for pregnancy prevention in women with BMI less than 30 kg/m2.
Overview
Norelgestromin and ethinyl estradiol is a transdermal contraceptive patch delivering approximately 150 mcg/day of norelgestromin and 35 mcg/day of ethinyl estradiol, indicated for pregnancy prevention in women with BMI less than 30 kg/m2.
Uses
Indicated for pregnancy prevention in women with BMI less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. May be less effective in women weighing 198 lbs or more.
Dosage
Apply one patch weekly for three weeks (21 days). Week four is patch-free. Use a 28-day cycle. Apply patches to upper outer arm, abdomen, buttock, or back. Do not cut or alter patches. Replace on the same day each week.
Side Effects
Most common adverse reactions (5% or greater): breast symptoms (22.4%), headache (21.0%), application site disorder (17.1%), and nausea (16.6%). Serious cardiovascular events and vascular thromboembolism may occur.
Interactions
Enzyme inducers (phenytoin, barbiturates, carbamazepine, St. John's wort) may decrease effectiveness. Use backup contraception. CYP3A4 inhibitors may increase hormone concentrations.
Warnings
Cigarette smoking increases serious cardiovascular event risk, contraindicated in women over 35 who smoke. Contraindicated in women with BMI 30 kg/m2 or greater due to increased VTE risk. Higher estrogen exposure may increase VTE risk compared to oral contraceptives. Discontinue if thromboembolic events occur. Stop 4 weeks before major surgery.
Pregnancy
No increased birth defect risk with inadvertent early use. Discontinue if pregnancy confirmed. Not recommended in nursing mothers; may reduce milk production.
Frequently Asked Questions
What is Norelgestromin And Ethinyl Estradiol used for?▼
Indicated for pregnancy prevention in women with BMI less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. May be less effective in women weighing 198 lbs or more.
What are the side effects of Norelgestromin And Ethinyl Estradiol?▼
Most common adverse reactions (5% or greater): breast symptoms (22.4%), headache (21.0%), application site disorder (17.1%), and nausea (16.6%). Serious cardiovascular events and vascular thromboembolism may occur.
Can I take Norelgestromin And Ethinyl Estradiol during pregnancy?▼
No increased birth defect risk with inadvertent early use. Discontinue if pregnancy confirmed. Not recommended in nursing mothers; may reduce milk production.
What are the important warnings for Norelgestromin And Ethinyl Estradiol?▼
Cigarette smoking increases serious cardiovascular event risk, contraindicated in women over 35 who smoke. Contraindicated in women with BMI 30 kg/m2 or greater due to increased VTE risk. Higher estrogen exposure may increase VTE risk compared to oral contraceptives. Discontinue if thromboembolic events occur. Stop 4 weeks before major surgery.
Related Medications
Vaccinia Immune Globulin Intravenous (human)
vaccinia immune globulin intravenous (human)
Human Immunoglobulin G [EPC]
11 DESCRIPTION VIGIV is a solvent/detergent-treated, filtered sterile solution of purified gamma globulin (IgG) fraction of human plasma containing antibodies to vaccinia virus. It is stabilized with 10% maltose and 0.03% polysorbate 80 (pH is between 5.0 and 6.5) and contains no preservative. The product is a clear to opalescent liquid.
Rituximab-arrx
rituximab-arrx
CD20-directed Cytolytic Antibody [EPC]
11 DESCRIPTION Rituximab-arrx is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab-arrx has an approximate molecular weight of 145 kD. Rituximab-arrx is produced in a mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium. RIABNI (rituximab-arrx) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for intravenous infusion.
Dextrose, Sodium Chloride, And Potassium Chloride
dextrose, sodium chloride, and potassium chloride
DESCRIPTION (See chart below for quantitative information.) Potassium Chloride in Dextrose and Sodium Chloride Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration. The formulas of the active ingredients are: Ingredients Molecular Formula Molecular Weight Sodium Chloride USP Potassium Chloride USP NaCl KCl 58.44 74.55 Hydrous Dextrose USP 198.17 Not made with natural rubber latex, PVC or DEHP.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.